# A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

> **NCT07141004** · PHASE4 · RECRUITING · sponsor: **Johnson & Johnson Private Limited** · enrollment: 100 (estimated)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** Guselkumab

## Key facts

- **NCT ID:** NCT07141004
- **Lead sponsor:** Johnson & Johnson Private Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-12
- **Primary completion:** 2027-06-05
- **Final completion:** 2027-09-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07141004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07141004, "A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07141004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*